The intent of this project was to calculate the expected event rate in a control population of patients at risk for a Major Adverse Cardiac Event (MACE). This information was used to inform enrollment in a clinical trial evaluating a candidate compound targeting a novel cardiovascular biomarker.
The project objective was to identify which candidate drug, among six in the customer’s clinical development pipeline, would offer the greatest long-term health outcomes and costs benefits.